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ORIGINAL ARTICLE
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Abstract
Background: The relationship between glycemic control and the risk of cardiac disease in patients with Type 2 Diabetes
Mellitus (T2DM) is controversial. 1,5-Anhydroglucitol (1,5-AG) is a biomarker of Glucose Variability (GV) and has been
associated with clinical cardiovascular disease. However, its association with Subclinical Cardiac Disease (SCD) is
unknown.
Aim of the work: Study the association between GV and SCD.
Subjects and methods: A cross-sectional study was conducted on 46 asymptomatic patients with T2DM as T2DM individuals group. Another 46 non-diabetic age and sex matched subjects were included as the healthy group. 1,5-AG was
measured for all subjects. M-mode echocardiography in parasternal long axis view was used to measure Left Ventricular
(LV) end diastolic dimension, LV end systolic dimension, ejection fraction, interventricular septum, LV posterior wall
thickness, LV fractional shortening, left atrial dimension and aortic root dimension. Global Longitudinal Strain (GLS)
was assessed by speckled tracking echocardiography.
Results: There were no signiﬁcant differences between both groups as regarding age, sex, BMI, AST, ALT, and serum
creatinine. 1,5-AG was lower in T2DM individuals group. As regarding the echo parameters no signiﬁcant difference
found between both groups regarding left ventricular, left atrial and aortic root dimensions. T2DM individuals group
showed a statistically signiﬁcant higher mitral valve area, apical 2 chambers, apical 4 chambers, apical longitudinal axis
and GLS. No correlation found between HbA1c and any echo parameters while 1,5-AG showed a signiﬁcantly negative
correlation with apical 2 chambers, apical 4 chambers, apical longitudinal axis and GLS. ROC curve analysis detected 1,5AG less than 7.51 ng/ml as the best cut off value with sensitivity of 85.7%, speciﬁcity 75% to diagnose patients with
T2DM and SCD.
Conclusion: 1,5-AG might be used as an additional surrogate marker to identify patients with T2DM and SCD.
Keywords: Glucose variability, Subclinical cardiac disease

1. Introduction

C

ardiovascular disease (CVD) is the major
cause of death in patients with type 2 Diabetes Mellitus (T2DM) [1]. It also has a

considerable impact on direct medical costs of
T2DM management [2]. Heart failure (HF) is the
most common presentation of CVD in patients
with T2DM [3]. 30-40% of patients with HF have
T2DM [4] and patients with T2DM have more
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than double the risk to develop HF [5]. The
prognosis of survival of those patients is almost
half the survival of non-diabetic population [6].
The American College of Cardiology Foundation/
American Heart Association (ACCF/AHA) classiﬁcation described patients with T2DM as stage
A HF even without any symptoms or structural
changes [7].
Before patients develop the full-blown picture of
HF, they pass into an asymptomatic (subclinical)
stage. Patients usually go undiagnosed during this
stage due to lack of screening programs [8]. Subclinical cardiac dysfunction can be detected by
decreased left ventricular ejection fraction (LVEF),
increased left atrial volume (LAV), and higher left
ventricular (LV) mass as measured by ordinary
echocardiography [9]. However, echocardiography
has two compromises. The ﬁrst is the difﬁculty to
detect early stages of the disease [10]. The second is
the great inter-person and intra-person variability
[11].
In recent years, cardiac strain has emerged as a
more sensitive measure of myocardial function.
Global longitudinal strain (GLS) assesses the total
deformation or shortening during the cardiac cycle
of longitudinal myocardial ﬁbers [12]. GLS may both
diagnose and exclude acute coronary syndrome
better than LVEF [13]. In a meta-analysis on 5721
patients from 15 clinical trials, GLS has better intraand inter-observer reproducibility compared to
LVEF [14]. That is why GLS is preferred in clinical
practice especially for mild systolic dysfunction [15].
Speckle tracking echocardiography is the most
recent method to detect subclinical cardiac function
[16].
Several mechanisms had been proposed to
explain the pathogenesis of HF in patients with
T2DM [17e19].
Although many studies showed improvement of
HF with improved glycemic control, other studies
failed to reach to the same conclusion [20]. Even it
may be exaggerated. For example, the incidence of
HF increased by 17% with tight glycemic control in a
meta-analysis on 3517 patients collected from 15
clinical trials [21]. Moreover, treatment of T2DM
with thiazolidendiones or insulin may increase the
incidence and risk of mortality due to HF [22]. All
these studies used glycated haemoglobin (HbA1c)
as a marker for glycemic control. They neglected a
recent measure of glycemic control which is diurnal
glucose variability (GV) that might be involved as a
surrogate marker of glycemic control.
Glucose variability refers to oscillations of blood
glucose that occur throughout the day including
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hypoglycemic periods and postprandial excursions
[23]. GV could be evaluated by continuous glucose
monitoring which is not feasible from the practical
point of view. 1,5-Anhydroglucitol (1,5- AG) is a
natural monosaccharide found in our food. It competes with glucose for tubular reabsorption so its
level decreases during times of hyperglycemia and
return to normal levels after approximately 2 weeks
in the absence of hyperglycemia [24]. It might be a
better predictor of short term glucose excursion and
GV than HbA1c in patients with T2DM [25].
GV may be a new predictor for the development
of adverse cardiac events [26]. Considering it as a
therapeutic target in addition to HbA1c might increase the sensitivity and speciﬁcity for the diagnosis of glycemic control.

2. Aim of the work
To study the association between GV measured
by 1,5-AG and subclinical cardiac disease measured
by speckle tracking echocardiography.

3. Subjects and methods
The present work is a cross sectional study. Based
on post review of literature that assumed on effect
size 0.7 and SD of 1.2, sample size has been calculated at 95% CT and power 80% and it was 46 participants/group. It involved 46 patients (18 males/28
females) with T2DM as the T2DM individuals group
and 46 healthy subjects (23 males/23 females) as the
healthy group after taking written consent from all
participants. Patients were recruited from the
outpatient diabetic clinic in Menouﬁya university
hospital and fever hospital during the period from
January 2019 to December 2019. Local ethical committee permission was obtained with the number 6/
2017INTM before the start of the study.
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Patients were included in the study if their Fasting
Plasma
Glucose
(FPG)

126
mg/dl,
PPPG  200 mg/dl or HbA1c  6.5% according to
the ADA guidelines 2018 [27] or if they are receiving
treatment for T2DM. All patients above 18 years
who fulﬁlled these criteria and accept signing the
consent were included in the study. 36 patients were
receiving oral anti-diabetic drugs, 14 patients
receiving insulin ± oral anti-diabetic drugs. Pregnant and breast feeding ladies as well as subjects
who refused to sign the consent were excluded from
the study. Patients with past history of cardiac,
renal, hepatic or advanced chest disease were also
excluded.
All patients were subjected to thorough history
taking, complete physical examination including
vital signs, general cardiac and abdominal examination in addition to anthropometric measurements. Blood samples were obtained from all
patients on their routine clinical visits after overnight fasting for at least 8 hours. Samples were
immediately centrifuged and serum stored at 80
C until assayed. FPG and PPPG were measured by
the glucose oxidase method. AST, ALT, HbA1c,
urea, and creatinine were measured by a routine
clinical chemistry laboratory analyzer.
1,5-AG was measured by enzyme linked immunosorbent assay (ELISA) KIT (SunRed, Shanghai,
China). This assay has 0.106 ng/ml sensitivity at
assay range from 0.2 to 30 ng/ml. Results were obtained using the microplate reader (ELx 808 TM
Absorbance microplate reader, BioTek) at wavelength 450 nm as recommended by the vendor.
Routine chest X ray and pelvi-abdominal ultrasound and 12- lead surface ECG were done for all
participants and patients with IHD were also
excluded from the study.
Conventional echocardiography
Echocardiographic examination was done by
using the commercially available Vivid 9, General
Electric Healthcare, Vingmed, Norway equipped
with a 1.7e4 MHz phased-array transducer. Echocardiographic imaging was obtained in the parasternal short and long axis, and apical 3, 2 and 4chambers views using standard transducer positions. LV end-systolic and diastolic volumes and
diameters, LV posterior and septal thickness, ejection fraction and left atrial and aortic diameter were
measured in accordance with the recommendations
of the American Society of echocardiography [28].
Continuous and pulsed wave Doppler was used for
assessment valvular function.
Doppler tissue imaging derived early mitral
annular velocity wave (E0 wave) was measured from
septal annular site in apical four chamber view and

the ratio of early mitral ﬂow E wave to the early
annular mitral wave (E/E0 ratio) was measured.
Left ventricular global strain by 2-D speckle
tracking echocardiography.
Three points in the LV were anchored, apex and
annular hinge points in apical 4, 3 & 2 chamber
views. Frame rate was selected between 40e90 or at
least 40% of HR. Then after activation of automated
function imaging, digital data were transferred for
off-line analysis, using Vivid Nine system Echo Pac,
GE Vingmed, Horton, Norway. The system processed the data and after ﬁnishing tracing and auto
processing of the three views, the global strain and
Bull's eye report were obtained. Peak LV Strain is
the peak negative value that was obtained at or
before aortic valve closure.

4. Statistical Analysis
Data were calculated using SPSS Version 21 and
given as the mean ± SD. The normality of data was
ﬁrst tested with one-sample Kolmogorov-Smirnov
test. Group differences were analyzed by Student's t
test, Mann-Whitney test, and X2 for normally
distributed, non-normally distributed, and noncontinuous variables respectively. Relationships
between 1,5-AG and HbA1c% with other factors
were assessed by Pearson correlation analysis. ROC
analysis was performed to study sensitivity, speciﬁcity and area under the curve (AUC) of 1,5-AG to
diagnose subclinical cardiac disease.
For all above mentioned statistical tests done, the
threshold of signiﬁcance is ﬁxed at 5% level (pvalue). The results was considered:
 Non-signiﬁcant when the probability of error is
more than 5% (p > 0.05).
 Signiﬁcant when the probability of error is less
than 5% (p  0.05).
The smaller the p-value obtained, the more signiﬁcant are the results.

5. Results
The present work included 46 (18 males/28 females) patients with T2DM with a duration of DM
15.23 ± 8.7 years as the T2DM individuals group.
Their age is 50.56 ± 11.77 years and BMI is
28.7 ± 3.83 kg/M2. In addition 46 apparently healthy
subjects were included as the healthy group. There
were no signiﬁcant differences between both groups
as regarding age, sex, BMI, AST, ALT, and serum
creatinine. As expected, the T2DM individuals
group showed higher FPG, PPPG and HbA1c than
the healthy group. 1,5-AG as an indicator of glucose

Table 1. Demographic and laboratory data of the studied groups.
T2DM individuals
N ¼ 46
Age (years)
Sex (Male/Female)
BMI (Kg/M2)
Serum creatinine (mg/dl)
ALT (mg/dl)
AST (mg/dl)
Fasting Plasma Glucose (mg/dl)
Post prandial Plasma Glucose (mg/dl)
HbA1c (%)
1,5 AG (ng/ml)

Healthy
N ¼ 46

Mean ± SD

Mean ± SD

50.56 ± 11.77
18/28
28.70 ± 3.83
0.86 ± 0.10
27.48 ± 7.10
30.41 ± 7.25
115.28 ± 22.37
151.87 ± 36.05
7.38 ± 1.09
6.23 ± 1.30

46.54 ± 14.19
23/23
27.22 ± 5.06
0.84 ± 0.08
25.59 ± 4.56
29.87 ± 7.70
76.33 ± 11.54
108.80 ± 15.49
5.33 ± 0.81
8.72 ± 2.23

t -test

P value

1.48
X2 ¼ 1.1
1.59
1.0
1.52
0.35
10.50
7.44
10.25
6.55

0.14
0.29
0.12
0.32
0.13
0.73
<0.001
<0.001
<0.001
<0.001

SD ¼ standard deviation, X2 ¼ Chi squared test.

variability was lower in the T2DM individuals group
(P < 0.001) (Table 1).
As regarding the echo parameters there were no
signiﬁcant difference between both groups
regarding LVEDD, LVESD, EF, IVSD, PWTd, FS, LA
dimension and Aortic root dimension. Peak velocity
of early diastolic mitral ﬂow wave (E wave), the ratio
of early (E wave) to late mitral ﬂow (A wave) velocities (E/A ratio) and mitral annular early diastolic
wave peak velocity (E0 wave) were lower in the
T2DM individuals group while E/E0 ratio and late
mitral ﬂow diastolic peak velocity were higher in
T2DM individuals group.
On the other hand, the T2DM individuals group
showed a statistically signiﬁcant lower apical 2

chambers, apical 4 chambers, apical longitudinal
axis and global strain pattern (Table 2) (Fig. 1).
No correlation found between HbA1c and any
echo parameters. On the other hand 1,5-AG showed
a signiﬁcantly negative correlation with apical 2
chambers, apical 4 chambers, apical longitudinal
axis and global strain pattern (Fig. 2) (Table 3).
Setting the mean value of the global strain pattern
of the healthy group 19.99% as the normal value,
ROC curve analysis was plotted to show the best cut
off value to diagnose subclinical cardiac disease. 1,5AG less than 7.51 ng/ml was the best cut off value
with sensitivity of 85.7%, speciﬁcity 75% and AUC
0.81 with accuracy of 84.8% at 95% CI 0.63-0.99
(Fig. 3).

Table 2. Comparison between the studied groups regarding Echo parameters.

IVSD (cm)
IVSS (cm)
LVIDd (cm)
LVIDs (cm)
LVPWD (cm)
LVPWS (cm)
EDV (ml)
ESV (ml)
EF (%)
SV (ml)
FS (%)
Aortic diameter (cm)
Lt. atrium diameter (cm)
MVE (m/sec)
MVA (m/sec)
MV (E/A)
 (m/sec)
E

E/E
Apical 2 chamber (%)
Apical 4 chamber (%)
Apical long axis (%)
Global strain pattern

T2DM individuals
N ¼ 46

Healthy
N ¼ 46

Mean ± SD

Mean ± SD

1.0 ± 0.13
1.5 ± 0.77
4.15 ± 0.88
3.4 ± 1.09
1.2 ± 0.51
1.53 ± 0.37
106.11 ± 26.74
42.5 ± 25.47
65.5 ± 4.52
66.98 ± 16.68
36.67 ± 7.36
3.05 ± 0.33
3.56 ± 0.71
0.66 ± 0.14
0.86 ± 0.20
0.80 ± 0.29
0.11 ± 0.19
9.71 ± 2.79
15.85 ± 6.66
16.11 ± 6.16
15.7 ± 3.2
15.86 ± 3.45

0.95 ± 0.17
1.38 ± 0.19
4.49 ± 0.61
3.19 ± 0.32
1.19 ± 0.57
1.44 ± 0.29
114.84 ± 20.93
37.17 ± 8.23
67.11 ± 4.02
73.89 ± 21.52
38.23 ± 5.43
2.95 ± 0.39
3.43 ± 0.42
0.81 ± 0.30
0.71 ± 0.20
1.18 ± 0.44
0.17 ± 0.26
8.44 ± 3.94
18.58 ± 10.98
18.94 ± 5.13
21.14 ± 2.69
19.99 ± 2.03

t-test

P value

1.76
0.12
1.61
0.86
1.31
1.32
1.75
0.59
1.80
1.72
1.16
1.39
1.08
3.04*
3.52*
4.73**
3.14*
2.20*
2.82*
2.39*
8.81**
6.96**

0.08
0.91
0.11
0.39
0.19
0.19
0.09
0.56
0.08
0.09
0.25
0.17
0.28
0.003
0.001
<0.001
0.002
0.03
0.006
0.02
<0.001
<0.001
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Fig. 1. Comparison of echo parameters between the T2DM individuals and the healthy groups.

6. Discussion
The present work showed a signiﬁcant difference
between diabetic and non-diabetic subjects as
 ratio. LV
regarding regional strain pattern and E/E
strain pattern is a sensitive parameter that detects
early left ventricular systolic dysfunction [29].
Asymptomatic diastolic dysfunction is an early
manifestation of cardiac dysfunction and precedes
the development of systolic dysfunction [30] [31].
Our ﬁnding conﬁrms the presence of asymptomatic
subclinical cardiac disease in patients with T2DM.
However the recent ADA guidelines do not recommend screening of asymptomatic high risk patients
with T2DM for CVD. They explained that by the
mandatory aggressive treatment to attain strict
metabolic goal in such patients whether symptomatic or asymptomatic and screening programs are
not coast effective [32]. This ideal way of thinking is

Fig. 2. correlation between 1,5-AG and global strain pattern in T2DM
individuals group.

not true [33]. In fact the majority of patients with
T2DM are not achieving good cardio-metabolic
goals [34]. In a prospective study on 154 asymptomatic patients with T2DM and preserved LVEF
50%, LV remodeling had progressed only in patients with low GLS less than 18% after 3 years of
follow up [35]. In addition, GLS was independently
associated with changes in both LV end-systolic and
end-diastolic volumes over 3-years period. Identifying those high risk patients with early diastolic
dysfunction narrows the scope and directives

Table 3. Correlation between both 1.5 AG and HbA1c and Echo
parameters.
1.5 AG

IVSD (cm)
IVSS (cm)
LVIDd (cm)
LVIDs (cm)
LVPWD (cm)
LVPWS (cm)
EDV (ml)
ESV (ml)
EF (%)
SV (ml)
FS (%)
Aortic diameter (cm)
Lt. atrium diameter (cm)
MVE (m/sec)
MVA (m/sec)
MV (E/A)
 (m/sec)
E
Apical 2 chamber (%)
Apical 4 chamber (%)
Apical long axis (%)
Global strain pattern
r ¼ correlation coefﬁcient.

HbA1c

r

P value

r

P value

0.19
0.25
0.08
0.009
0.05
0.12
0.01
0.17
0.22
0.20
0.11
0.02
0.12
0.12
0.009
0.09
0.19
0.48*
0.45*
0.54*
0.46*

0.20
0.09
0.61
0.95
0.77
0.43
0.94
0.25
0.16
0.19
0.47
0.91
0.42
0.43
0.95
0.54
0.20
0.001
0.002
<0.001
0.001

0.11
0.15
0.06
0.09
0.007
0.20
0.003
0.08
0.18
0.04
0.19
0.25
0.26
0.01
0.05
0.08
0.27
0.18
0.21
0.27
0.28

0.47
0.31
0.69
0.56
0.96
0.19
0.98
0.60
0.25
0.81
0.21
0.10
0.09
0.95
0.74
0.62
0.07
0.12
0.08
0.07
0.06

Fig. 3. ROC curve of 1.5AG (at a GLS ¼ 19.99) for detection of
subclinical cardiac disease in patients with T2DM.

aggressive early management to prevent the progression to HF.
Although the risk of HF in patients with T2DM is
well established, the beneﬁcial role of glycemic
control as evaluated by HbA1c is questionable. In a
meta-analysis study on 37229 patients with T2DM,
no association was found between the degree of
glycemic control and the risk of HF [20]. Similarly,
Paolillos and colleagues found no relation between
HbA1c% and long term prognosis of HF if HbA1c is
below 8% in a recent study done on 3927 patients
with T2DM and HF followed up for 3.66 years [36].
These ﬁndings are similar to our results as we did
not ﬁnd a correlation between HbA1c and all measures of cardiac function. On the other hand very
poor glycemic control was found to be associated
with increased incidence of HF in patients with
T2DM [37]. Putting these contradictory data
together may indicate the presence of another
player than HbA1c that link the glycemic control
with the development and progression of HF in
patients with T2DM.
Our results showed a signiﬁcant negative correlation between global strain pattern and 1,5-AG. So
GV (represented by 1,5-AG) seems to be a new
stronger link between glycemic control and subclinical cardiac disease. Previous reports conﬁrmed
the link between GV and myocardial damage and
mortality [38] [39,40]. Few studies reported the association of 1,5-AG with subclinical cardiac disease.
Menglu Liang and coworkers proved the association
between 1,5-AG and myocardial damage as
measured by high-sensitivity cardiac troponin T
among 9145 asymptomatic patients with T2DM.
However they did not study the link between 1,5AG and cardiac function [41].
Recently, Tang et al conﬁrmed the association
between GV and left ventricular function on 445

495

patients with T2DM [42]. Their work however is less
valuable if compared to our work as they depended
on visit to visit variability in fasting plasma glucose.
They also used routine echocardiography to evaluate the cardiac function which misses a lot of cases
with early dysfunction. To the best of our knowledge, our work is the ﬁrst to address the link between GV and subclinical cardiac function as
measured by speckled tracing echocardiography.
ROC curve analysis showed that 1,5-AG less than
7.51 ng/ml was the best cut off value to detect patients with global strain pattern below the mean of
the healthy group (19.99%). The test has sensitivity
of 85.7%, speciﬁcity 75% and AUC 0.81 with accuracy of 84.8% at 95% CI 0.63-0.99. Based on these
results, 1,5-AG might be used as a simple biomarker
which can early predict SCD specially when HbA1c
is below 7%. Patients with 1,5-AG less than 7.51 are
at increased risk of subclinical cardiac disease which
is more risky to develop HF in the future. These
results explain previous reports that showed the
independent association between GV and increased
mortality in patients with acute HF [43]. It should be
noted that to fundamentally change clinical care
with use of this new metrics based on our results is
missing. It would be important to demonstrate that
the metrics relate to and predict clinical outcomes.
In this regard, studies including more patients and
longer-term studies relating this outcome with diabetes complications are needed.

7. Limitations
Our work was not a mechanistic trial to explain
how GV can induce HF. The correlation found between 1,5-AG and global strain pattern is weak, but
signiﬁcant. Previous studies explained this association through endothelial apoptosis by overproduction of reactive oxygen species [44]. The
present work is a cross sectional trial. Prospective
trials on a larger numbers of patients are needed to
conﬁrm our results.

8. Conclusion
Patients with T2DM have asymptomatic subclinical cardiac disease. Glucose variability in addition to
hyperglycemia is associated with the risk of HF. 1,5AG might be used as a novel reproducible
biomarker that can predict subclinical cardiac disease in patients with T2DM.
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